Literature DB >> 2876451

Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group.

.   

Abstract

The selective serotonin reuptake inhibitor citalopram was compared with clomipramine in a multicenter clinical study. From a total of 150 depressed patients (age 18-65 years), 114 patients with a Hamilton Depression Scale (HDS) total score greater than or equal to 18 at the end of a 1 week placebo period were started on treatment with either citalopram (40 mg/day) or clomipramine (150 mg/day) (fixed, single daily dose). Patients stratified according to diagnostic rating (Newcastle Inventory, endogenous/non-endogenous) were randomly allocated to treatment groups using double blind principles. In total, 102 patients completed more than 2 weeks, treatment and were included in the analyses of therapeutic effect. The two drug groups were comparable in terms of sex, age, and departmental distribution. Categorical measurements of therapeutic effect based on the HDS total score showed that in the endogenously depressed patients a significantly higher percentage of patients on clomipramine (n = 37) than on citalopram (n = 38) were classified as complete responders (HDS total less than or equal to 7) after 3, 4 and 5 weeks of treatment. In the non-endogenously depressed patients (clomipramine: n = 15, citalopram: n = 12) rather similar numerical differences were observed (P less than 0.05 at 5th week). In the total patient group the percentage of complete response after 5 weeks was about 60 in the clomipramine group (n = 52) and about 30 in the citalopram group (n = 50) (P less than 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876451     DOI: 10.1007/bf00172884

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Experimental studies of the therapeutic action of electroconvulsive therapy in endogenous depression. The role of the electrical stimulation and of the seizure studied by variation of stimulus intensity and modification by lidocaine of seizure discharge.

Authors:  B CRONHOLM; J O OTTOSSON
Journal:  Acta Psychiatr Scand Suppl       Date:  1960

2.  Clinical response and tricyclic plasma levels during treatment with clomipramine.

Authors:  L Della Corte; A D Broadhurst; G P Sgaragli; S Filippini; A F Heeley; H D James; C Faravelli; A Pazzagli
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

3.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

Review 4.  Current concepts of the mechanisms of action of antidepressant drugs.

Authors:  M F Sugrue
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

5.  Clomipramine: plasma levels and clinical effects.

Authors:  N Reisby; L F Gram; P Bech; F Sihm; O Krautwald; J Elley; J Ortmann; J Christiansen
Journal:  Commun Psychopharmacol       Date:  1979

6.  Quantitative determination of imipramine and desipramine in human blood plasma by direct densitometry of thin-layer chromatograms.

Authors:  A Nagy; L Treiber
Journal:  J Pharm Pharmacol       Date:  1973-08       Impact factor: 3.765

7.  Plasma levels and antidepressive effect of imipramine.

Authors:  L F Gram; N Reisby; I Ibsen; A Nagy; S J Dencker; P Bech; G O Petersen; J Christiansen
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

8.  Correlation of subjective side effects with plasma concentrations of nortriptyline.

Authors:  M Asberg; B Cronholm; F Sjöqvist; D Tuck
Journal:  Br Med J       Date:  1970-10-03

9.  Cardiovascular effect of imipramine and nortriptyline in elderly patients.

Authors:  P Thayssen; M Bjerre; P Kragh-Sørensen; M Møller; O L Petersen; C B Kristensen; L F Gram
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Orthostatic side effects of clomipramine and citalopram during treatment for depression.

Authors:  P Christensen; H Y Thomsen; O L Pedersen; L F Gram; P Kragh-Sørensen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  37 in total

Review 1.  Fortnightly review: drug treatment of depression.

Authors:  O Spigset; B Mårtensson
Journal:  BMJ       Date:  1999-05-01

Review 2.  Efficacy of fluvoxamine in severe depression.

Authors:  J Mendlewicz
Journal:  Drugs       Date:  1992       Impact factor: 9.546

3.  A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients.

Authors:  Walter W van den Broek; Tom K Birkenhäger; Paul G H Mulder; Jan A Bruijn; Peter Moleman
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

Review 4.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

5.  Single-action versus dual-action antidepressants.

Authors:  Rakesh Jain
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 6.  Remission from depression : a review of venlafaxine clinical and economic evidence.

Authors:  Donald Han; Edward C Y Wang
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.

Authors:  S Weinmann; T Becker; M Koesters
Journal:  Psychopharmacology (Berl)       Date:  2007-10-23       Impact factor: 4.530

8.  Translating evidence on depression and physical symptoms into effective clinical practice.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 9.  Severe depression: is there a best approach?

Authors:  S B Sonawalla; M Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

10.  An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Authors:  Joachim Wernicke; Alberto Lledó; Joel Raskin; Daniel K Kajdasz; Fujun Wang
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.